Global Liver Cirrhosis Market 2016-2020

  • ID: 3721868
  • Report
  • Region: Global
  • 74 pages
  • TechNavio
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 5

FEATURED COMPANIES

  • Bristol-Myers Squibb
  • F Hoffman La-Roche
  • GlaxoSmithKline
  • Intercept Pharmaceuticals
  • Merck
  • Norgine
  • MORE
About Cirrhosis of the Liver

Cirrhosis of the liver (or liver fibrosis) is a serious condition in which the liver stops functioning properly due to damage and irreversible scarring of the liver tissue. The scarring of the tissue is often caused by long-term exposure to viral infections and toxins such as alcohol. Chronic viral hepatitis and non-alcoholic steatohepatitis can also cause liver cirrhosis. Alcohol-related medications, antiviral medications, and metal chelating agents are used in the treatment of the causes of liver cirrhosis while antibiotics, vitamins, corticosteroids, diuretics, beta-blockers, and laxatives are used for the treatment of the complications of the disease.

The analysts forecast the global liver cirrhosis therapeutics market to grow at a CAGR of 4.36% during the period 2016-2020.

Covered in this report
The report covers the present scenario and the growth prospects of the global liver cirrhosis therapeutics market for 2016-2020. To calculate the market size, the report considers the revenue generated from the sales of prescription, generic, and off-label drugs used in the treatment of liver cirrhosis.

The market is divided into the following segments based on geography:
- Americas
- APAC
- EMEA

The report, Global Liver Cirrhosis Therapeutics Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors
- F Hoffman La-Roche
- GlaxoSmithKline
- Gilead Sciences
- Johnson & Johnson
- Merck

Other prominent vendors
- Bristol-Myers Squibb
- Conatus Pharmaceuticals
- Gwo Xi Stem Cell Applied Technology
- Instituto Grifols
- Intercept Pharmaceuticals
- NGM Biopharmaceuticals
- Norgine
- Pharmicell
- Salix Pharmaceuticals
- Stempeutics Research

Market drivers
- High prevalence of liver cirrhosis
- For a full, detailed list, view the full report

Market challenges
- Adverse effects of drugs
- For a full, detailed list, view the full report

Market trends
- Use of off-label drugs
- For a full, detailed list, view the full report

Key questions answered in this report
- What will the market size be in 2020 and what will the growth rate be?
- What are the key market trends?
- What is driving this market?
- What are the challenges to market growth?
- Who are the key vendors in this market space?
- What are the market opportunities and threats faced by the key vendors?
- What are the strengths and weaknesses of the key vendors?

You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Bristol-Myers Squibb
  • F Hoffman La-Roche
  • GlaxoSmithKline
  • Intercept Pharmaceuticals
  • Merck
  • Norgine
  • MORE
PART 01: Executive summary
  • Highlights
PART 02: Scope of the report
  • Market overview
  • Top-vendor offerings
PART 03: Market research methodology
  • Research methodology
  • Economic indicators
PART 04: Introduction
  • Key market highlights
PART 05: Disease overview
  • Understanding the disease
  • Etiology
  • Symptoms
  • Pathophysiology
  • Diagnosis
  • Epidemiology
  • Prevention
  • Treatment
  • Impact of alcohol consumption on liver cirrhosis
PART 06: Pipeline portfolio
  • Information on pipeline candidates
  • Clinical trials for liver cirrhosis
PART 07: Market landscape
  • Market overview
  • Market size and forecast
  • Five forces analysis
PART 08: Market segmentation by type of molecule
  • Biologics
  • Small molecules
PART 09: Market segmentation by types of liver cirrhosis

PART 10: Market segmentation by types of liver cirrhosis treatment
  • Medications to treat causes of liver cirrhosis
  • Medications to treat complications of liver cirrhosis
PART 11: Geographical segmentation
  • Liver cirrhosis medication market in Americas
  • Market overview
  • Market size and forecast
  • Liver cirrhosis medication market in EMEA
  • Market overview
  • Market size and forecast
  • Liver cirrhosis medication market in APAC
  • Market overview
  • Market size and forecast
PART 12: Market drivers
  • High prevalence of liver cirrhosis
  • Advances in technology
  • High unmet medical needs
  • Changes in lifestyle
PART 13: Impact of drivers

PART 14: Market challenges
  • Use of alternative therapies
  • Adverse effects of drugs
  • Poor patient adherence
  • Stringent regulatory guidelines
PART 15: Impact of drivers and challenges

PART 16: Market trends
  • Rise in public awareness
  • Increase in R&D
  • Use of off-label drugs
  • Patient assistance programs
PART 17: Vendor landscape
  • Competitive scenario
  • F Hoffmann-La Roche
  • GlaxoSmithKline
  • Gilead Sciences
  • Johnson & Johnson
  • Merck
  • Other prominent vendors
PART 18: Appendix
  • List of abbreviations
PART 19: About the Author

List of Exhibits
Exhibit 01: Product offerings
Exhibit 02: Stages of liver diseases
Exhibit 03: Causes of liver cirrhosis
Exhibit 04: Diagnosis of liver cirrhosis
Exhibit 05: Effect of alcohol consumption on liver cirrhosis
Exhibit 06: Pipeline molecules for liver cirrhosis
Exhibit 07: Clinical trials by development phase
Exhibit 08: Clinical trials by trial status
Exhibit 09: Global liver cirrhosis medication market 2015-2020 ($ billions)
Exhibit 10: Five forces analysis
Exhibit 11: Four main types of liver cirrhosis
Exhibit 12: Market share by types of liver cirrhosis
Exhibit 13: Types of treatment for liver cirrhosis
Exhibit 14: Global liver cirrhosis medication market segment by geography 2015
Exhibit 15: Global liver cirrhosis medication market segment by geography 2015-2020 ($ millions)
Exhibit 16: Liver cirrhosis medication market in Americas ($ millions)
Exhibit 17: Liver cirrhosis medication market in EMEA ($ millions)
Exhibit 18: Liver cirrhosis medication market in APAC ($ billions)
Exhibit 19: Impact of drivers
Exhibit 20: Impact of drivers and challenges
Exhibit 21: F Hoffmann-La Roche: Business segmentation 2014 by revenue
Exhibit 22: F Hoffmann-La Roche: Business segmentation by revenue 2013 and 2014 ($ billions)
Exhibit 23: F Hoffmann-La Roche: Geographical segmentation by revenue 2014
Exhibit 24: F Hoffmann-La Roche: YoY growth and revenue of Pegasys 2012-2014 ($ billions)
Exhibit 25: F Hoffmann-La Roche: Key takeaways
Exhibit 26: GlaxoSmithKline: Business segmentation by revenue 2014
Exhibit 27: GlaxoSmithKline: Business segmentation by revenue 2013 and 2014 ($ billions)
Exhibit 28: GlaxoSmithKline: Geographical segmentation by revenue 2014
Exhibit 29: GlaxoSmithKline: YoY growth and revenue of Epivir 2012-2014 ($ millions)
Exhibit 30: Gilead Sciences: Geographical segmentation by revenue 2014
Exhibit 31: Gilead Sciences: YoY revenue comparison of Sovaldi 2013-2014 ($ millions)
Exhibit 32: Gilead Sciences: YoY growth and revenue of Viread 2012-2014 ($ millions)
Exhibit 33: Gilead Sciences: Key takeaways
Exhibit 34: Johnson & Johnson: Business segmentation by revenue 2014
Exhibit 35: Johnson & Johnson: Business segmentation by revenue 2013 and 2014 ($ billions)
Exhibit 36: Johnson & Johnson: Geographical segmentation by revenue 2014
Exhibit 37: Johnson & Johnson: YoY growth and revenue of Incivo 2012-2014 ($ millions)
Exhibit 38: Johnson & Johnson: YoY revenue growth of Olysio 2012-2014 ($ millions)
Exhibit 39: Johnson & Johnson: Key takeaways
Exhibit 40: Merck: Business segmentation by revenue 2014
Exhibit 41: Merck: Business segmentation by revenue 2013 and 2014 ($ billions)
Exhibit 42: Merck: Geographical segmentation by revenue 2014
Exhibit 43: Merck: YoY growth and revenue of PegIntron 2012-2014 ($ millions)
Exhibit 44: Merck: YoY growth and revenue of Victrelis 2012-2014 ($ millions)
Exhibit 45: Merck: Key takeaways
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5

FEATURED COMPANIES

  • Bristol-Myers Squibb
  • F Hoffman La-Roche
  • GlaxoSmithKline
  • Intercept Pharmaceuticals
  • Merck
  • Norgine
  • MORE
New Report Released: – Global Liver Cirrhosis Therapeutics Market 2016-2020

The author of the report recognizes the following companies as the key players in the global liver cirrhosis therapeutics market: F Hoffman La-Roche, GlaxoSmithKline, Gilead Sciences, Johnson & Johnson, and Merck.

Other Prominent Vendors in the market are: Bristol-Myers Squibb, Conatus Pharmaceuticals, Gwo Xi Stem Cell Applied Technology, Instituto Grifols, Intercept Pharmaceuticals, NGM Biopharmaceuticals, Norgine, Pharmicell, Salix Pharmaceuticals, and Stempeutics Research.

Commenting on the report, an analyst from the research team said: “A noticeable trend in the market is the use of off-label drugs. Off-label drugs are unapproved medications that are used in the treatment of diseases. For instance, apart from multivitamins and mineral supplements, disulfiram, naltrexone, acamprosate, ciprofloxacin, norfloxacin, ceftriaxone, ofloxacin, amoxicillin-clavulanate, and phytonadione are among the off-label drugs available for the treatment of liver cirrhosis.”

According to the report, a growth driver of this market is the high prevalence of liver cirrhosis. Alcohol has been identified as the strongest risk factor for liver cirrhosis, other than diabetes and hepatitis C, which together constitutes for over 50% of all cirrhosis cases. Relevant health efforts are required to reduce this disease burden, specifically among ethnic minorities and individuals living below the poverty level. As per a studies published, liver cirrhosis affects over 633,000 people every year. It also stated that more than 68% of these individuals may not know that they have the disease, raising the possibility of a large number of undiagnosed cases of liver cirrhosis.

Further, the report states that a challenge that could impact market growth is the adverse effects of drugs used to treat this medical issue.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Note: Product cover images may vary from those shown
5 of 5
- F Hoffman La-Roche
- GlaxoSmithKline
- Gilead Sciences
- Johnson & Johnson
- Merck
- Bristol-Myers Squibb
- Conatus Pharmaceuticals
- Gwo Xi Stem Cell Applied Technology
- Instituto Grifols
- Intercept Pharmaceuticals
- NGM Biopharmaceuticals
- Norgine
- Pharmicell
- Salix Pharmaceuticals
- Stempeutics Research.
Note: Product cover images may vary from those shown
6 of 5
Note: Product cover images may vary from those shown
Adroll
adroll